Hongzhe Sun

Hongzhe Sun

Auto-generated profile, based on publicly available information

Hongzhe Sun

Department of Chemistry, The University of Hong Kong, Hong Kong SAR, P. R. China

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
RWRunming Wang
Runming Wang
TLTsz-Pui Lai
Tsz-Pui Lai
PGPeng GAO
Peng GAO
HZHongmin Zhang
Hongmin Zhang
PHPak-Leung HO
Pak-Leung HO
HSHongzhe Sun
Hongzhe Sun
Drug-resistant superbugs pose a huge threat to human health. Infections by Enterobacteriaceae producing metallo-β-lactamases (MBLs), e.g., New Delhi metallo-β-lactamase 1 (NDM-1) are very difficult to treat. Development of effective MBL inhibitors to revive the efficacy of existing antibiotics is highly desirable. However, such inhibitors are not clinically available till now. Here we show that an anti-Helicobacter pyloridrug, colloidal bismuth subcitrate (CBS), and related Bi(III) compounds irreversibly inhibit different types of MBLs via the mechanism, with one Bi(III) displacing two Zn(II) ions as revealed by X-ray crystallography, leading to the release of Zn(II) cofactors. CBS restores meropenem (MER) efficacy against MBL-positive bacteria in vitro, and in mice infection model, importantly, also slows down the development of higher-level resistance in NDM-1-positive bacteria. This study demonstrates a high potential of Bi(III) compounds as the first broad-spectrum B1 MBL inhibitors to treat MBL-positive bacterial infection in conjunction with existing carbapenems.

17 September 2021 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
DGDarren Griffith
Darren Griffith
HLHongyan Li
Hongyan Li
MWMelissa V. Werrett
Melissa V. Werrett
PAPhilip C. Andrews
Philip C. Andrews
HSHongzhe Sun
Hongzhe Sun
Bismuth-based compounds have been used extensively as medicines for the treatment of gastrointestinal disorders and H. pylori infections. Bismuth compounds and Bi-based nanomaterials show promise for emerging infectious diseases, cancer ( e.g. 213 Bi) and also imaging.

16 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SYShuofeng Yuan
Shuofeng Yuan
Xin YinXin Yin
Xin Yin
XMXiangzhi Meng
Xiangzhi Meng
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
ZYZi-Wei Ye
Zi-Wei Ye
KYKwok-Yung Yuen
Kwok-Yung Yuen

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HWHaibo Wang
Haibo Wang
MWMinji Wang
Minji Wang
XXXiaohan Xu
Xiaohan Xu
PGPeng Gao
Peng Gao
ZXZeling Xu
Zeling Xu
HSHongzhe Sun
Hongzhe Sun
The rapid emergence of drug resistant Staphylococcus aureus (S. aureus) poses a serious threat to public health globally. Silver (Ag)-based antimicrobials are promising to combat antibiotic resistant S. aureus, yet their molecular targets are largely elusive. Herein, we separate and identify 38 authentic Ag+-binding proteins in S. aureus at the whole-cell scale. We then capture the molecular snapshot on the dynamic action of Ag+ against S. aureus and further validate that Ag+ could inhibit a key target 6-phosphogluconate dehydrogenase through binding to catalytic His185 by X-ray crystallography. Significantly, the multi-target mode of action of Ag+ (and nanosilver) endows its sustainable antimicrobial efficacy, leading to enhanced efficacy of conventional antibiotics and resensitization of MRSA to antibiotics. Our study resolves the long-standing question of the molecular targets of silver in S. aureus and offers insights into the sustainable bacterial susceptibility of silver, providing a potential approach for combating antimicrobial resistance.

7 October 2020 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
SYShuofeng Yuan
Shuofeng Yuan
RWRunming Wang
Runming Wang
JCJasper Fuk-Woo Chan
Jasper Fuk-Woo Chan
AZAnna Jinxia Zhang
Anna Jinxia Zhang
TCTianfan Cheng
Tianfan Cheng
HSHongzhe Sun
Hongzhe Sun
SARS-CoV-2 is causing a pandemic of COVID-19, with high infectivity and significant mortality1. Currently, therapeutic options for COVID-19 are limited. Historically, metal compounds have found use as antimicrobial agents, but their antiviral activities have rarely been explored. Here, we test a set of metallodrugs and related compounds, and identify ranitidine bismuth citrate, a commonly used drug for the treatment of Helicobacter pylori infection, as a potent anti-SARS-CoV-2 agent, both in vitro and in vivo. Ranitidine bismuth citrate exhibited low cytotoxicity and protected SARS-CoV-2-infected cells with a high selectivity index of 975. Importantly, ranitidine bismuth citrate suppressed SARS-CoV-2 replication, leading to decreased viral loads in both upper and lower respiratory tracts, and relieved virus-associated pneumonia in a golden Syrian hamster model. In vitro studies showed that ranitidine bismuth citrate and its related compounds exhibited inhibition towards both the ATPase (IC50 = 0.69 µM) and DNA-unwinding (IC50 = 0.70 µM) activities of the SARS-CoV-2 helicase via an irreversible displacement of zinc(ii) ions from the enzyme by bismuth(iii) ions. Our findings highlight viral helicase as a druggable target and the clinical potential of bismuth(iii) drugs or other metallodrugs for the treatment of SARS-CoV-2 infection.

1 April 2012 in Current Opinion in Chemical Biology
Verified
Journal Article
Open access
HLHongyan Li
Hongyan Li
HSHongzhe Sun
Hongzhe Sun
Bismuth has been used in medicine for over two centuries for the treatment of various diseases, in particular for gastrointestinal disorders, owing to its antimicrobial activity. Recent structural characterization of bismuth drugs provides an insight into assembly and pharmacokinetic pathway of the drugs. Mining potential protein targets inside the pathogen via metallomic/metalloproteomic approach and further characterization on the interactions of bismuth drugs with these targets laid foundation in understanding the mechanism of action of bismuth drugs. Such studies would be beneficial in rational design of new potential drugs.